Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
New Rules On Development of Veterinary Drugs That Can Affect Food Supplies
Of interest to veterinary medicine manufacturers is a final guidance document issued by the FDA titled “Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing” (VICH GL28). The guidance was adapted for veterinary use by the International Cooperation on Harmonisation of Technical Require-ments for Registration of Veterinary Medicinal Products (VICH) from a guidance regarding pharmaceuticals for human use. It's intended to help ensure that residues of veterinary drugs in animal products for human consumption are not too carcinogenic and applies to food in the European Union, Japan, and the United States. Copies of the document may be obtained on the Internet from the CVM home page at http://www.fda.gov/cvm. For more information, see Docket No. 2001D-0357 at http://a257.g.akamaitech.net/ 7/257/2422/14mar20010800/edocket.access.gpo.gov/2004/04-11781.htm
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.